Zobrazeno 1 - 10
of 4 901
pro vyhledávání: '"relapsed refractory"'
Autor:
Yuhan Yan, Yixuan Tu, Qian Cheng, Jian Zhang, Erhua Wang, Zuqun Deng, Yan Yu, Liwen Wang, Rui Liu, Ling Chu, Liqing Kang, Jing Liu, Xin Li
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-13 (2024)
Abstract Background B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR T-cell) therapy has exhibited remarkable efficacy in refractory or relapsed multiple myeloma (R/R MM), but recurrence and rapid progression of disease
Externí odkaz:
https://doaj.org/article/a60950bfb0a443be87c9a362b63aaf60
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background As we delve into the intricate world of venetoclax combination therapy in relapsed or refractory acute myeloid leukemia (AML), our exploration not only aims to contribute to the current body of knowledge but also strives to inform
Externí odkaz:
https://doaj.org/article/c45798f47326429a914cb9f7c8578e0b
Autor:
S. K. Zyryanov, I. N. Dyakov
Publikováno v:
Фармакоэкономика, Vol 17, Iss 2, Pp 129-136 (2024)
Objective: to conduct a clinical and economic study of acalabrutinib for the treatment of adult patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy in the Russian Federation.Material and
Externí odkaz:
https://doaj.org/article/338b38071e0947d4a72c818883742e92
Autor:
Manlio Fazio, Chiara Maria Catena Sorbello, Vittorio Del Fabro, Alessandra Romano, Maria Teresa Cannizzaro, Nunziatina Laura Parrinello, Benedetta Esposito, Sara Frazzetto, Federica Elia, Francesco Di Raimondo, Concetta Conticello
Publikováno v:
Hematology Reports, Vol 16, Iss 3, Pp 541-551 (2024)
Neoplastic plasma cells (PCs) proliferation at anatomic sites dislocated from the bone marrow (BM) or their contiguous growth from osseous lesions that disrupt the cortical bone is termed extramedullary multiple myeloma (EMD). EMD still remains chall
Externí odkaz:
https://doaj.org/article/11046c4e4c2847b4bf27b2213c705ae2
Autor:
Xiaodan Luo, Ao Chen, Le Qin, Robert Weinkove, Rong Zhao, Ting Ye, Sihui Chen, Jianli Tang, Jianbo Liu, Jiayu Huang, Boyun Shi, Danyun Yuan, Huo Tan, Dajiang Qin, Zhaoyang Tang, Peng Li, Runhui Zheng
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
This study explores a novel therapeutic strategy for relapsed/refractory (R/R) Burkitt lymphoma (BL) by integrating autologous hematopoietic stem cell transplantation (ASCT) with tandem anti-CD19/CD22 chimeric antigen receptor (CAR) T cell therapy. A
Externí odkaz:
https://doaj.org/article/d4ff5b585ed24d0483cf954e0964fad6
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionPeripheral T-cell lymphomas (PTCLs) have poor outcomes in the relapsed/refractory (R/R) setting. In this study, we evaluated the efficacy of dexamethasone, L-asparaginase, ifosfamide, carboplatin, and etoposide (DL-ICE) chemotherapy follo
Externí odkaz:
https://doaj.org/article/06048182c18f4e7cb729df15909255e9
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Acute myeloid leukemia (AML) is a severe hematological malignancy with poor outcomes, particularly in older adults. Traditional treatment options like high-dose chemotherapy often lead to refractory or relapsed AML, with even worse outcomes. New ther
Externí odkaz:
https://doaj.org/article/77703c69b7174e65888d0285437e922f
Autor:
Chieh-Lin Jerry Teng, Su-Peng Yeh, Tsai-Yun Chen, Yu-Chin Hung, Yun-Chu Lin, Sin Syue Li, Ming-Chung Wang, Shang-Yi Huang
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
Background/purpose The treatment landscape of relapsed/refractory multiple myeloma (RRMM) is rapidly evolving in Taiwan. The present study aimed to assess the treatment patterns among RRMM patients in Taiwan.Methods This retrospective, chart review-b
Externí odkaz:
https://doaj.org/article/9593eb70b29941de9fe5b26697691dd5
Autor:
Ziyi Hao, Yingying Fei, Juan Chen, Sailan Huang, Li Wang, Youhuan Yu, Meiru Bian, Yejun Si, Xingxia Zhang, Xiaotian Yang, Bing Zhang, Yan Wan, Guoqiang Lin, Yanming Zhang
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
Objectives: Relapsed/refractory acute B-cell lymphoblastic leukemia (R/R B-ALL) often responds poorly to induction chemotherapy. However, recent research has shown a novel and effective drug treatment for R/R B-ALL.Methods: A total of eight patients
Externí odkaz:
https://doaj.org/article/8b52a6c0ae8f44cdb0db680bdba9c427
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
ABSTRACTPatients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) require additional treatments, especially those not eligible or not responding to high dose cytotoxic chemotherapy and stem cell transplantation. Over the last f
Externí odkaz:
https://doaj.org/article/67c75f5223d94dd089953e5ef432e992